S&P 500   5,258.09 (+0.18%)
DOW   39,811.48 (+0.13%)
QQQ   444.20 (-0.14%)
AAPL   171.75 (-0.90%)
MSFT   420.47 (-0.23%)
META   487.49 (-1.29%)
GOOGL   150.91 (+0.03%)
AMZN   180.16 (+0.18%)
TSLA   176.35 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.51 (-3.43%)
AMD   180.40 (+0.45%)
BABA   72.47 (+1.23%)
T   17.64 (+0.51%)
F   13.19 (+1.00%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   175.09 (-2.79%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.91 (+0.47%)
PYPL   67.13 (+0.84%)
XOM   116.06 (+0.95%)
S&P 500   5,258.09 (+0.18%)
DOW   39,811.48 (+0.13%)
QQQ   444.20 (-0.14%)
AAPL   171.75 (-0.90%)
MSFT   420.47 (-0.23%)
META   487.49 (-1.29%)
GOOGL   150.91 (+0.03%)
AMZN   180.16 (+0.18%)
TSLA   176.35 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.51 (-3.43%)
AMD   180.40 (+0.45%)
BABA   72.47 (+1.23%)
T   17.64 (+0.51%)
F   13.19 (+1.00%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   175.09 (-2.79%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.91 (+0.47%)
PYPL   67.13 (+0.84%)
XOM   116.06 (+0.95%)
S&P 500   5,258.09 (+0.18%)
DOW   39,811.48 (+0.13%)
QQQ   444.20 (-0.14%)
AAPL   171.75 (-0.90%)
MSFT   420.47 (-0.23%)
META   487.49 (-1.29%)
GOOGL   150.91 (+0.03%)
AMZN   180.16 (+0.18%)
TSLA   176.35 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.51 (-3.43%)
AMD   180.40 (+0.45%)
BABA   72.47 (+1.23%)
T   17.64 (+0.51%)
F   13.19 (+1.00%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   175.09 (-2.79%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.91 (+0.47%)
PYPL   67.13 (+0.84%)
XOM   116.06 (+0.95%)
S&P 500   5,258.09 (+0.18%)
DOW   39,811.48 (+0.13%)
QQQ   444.20 (-0.14%)
AAPL   171.75 (-0.90%)
MSFT   420.47 (-0.23%)
META   487.49 (-1.29%)
GOOGL   150.91 (+0.03%)
AMZN   180.16 (+0.18%)
TSLA   176.35 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.51 (-3.43%)
AMD   180.40 (+0.45%)
BABA   72.47 (+1.23%)
T   17.64 (+0.51%)
F   13.19 (+1.00%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   175.09 (-2.79%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.91 (+0.47%)
PYPL   67.13 (+0.84%)
XOM   116.06 (+0.95%)
NASDAQ:PRPO

Precipio (PRPO) Stock Price, News & Analysis

$6.26
+0.06 (+0.97%)
(As of 11:11 AM ET)
Today's Range
$6.01
$6.26
50-Day Range
$5.96
$6.89
52-Week Range
$4.75
$15.41
Volume
2,552 shs
Average Volume
6,382 shs
Market Capitalization
$8.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00

Precipio MarketRank™ Stock Analysis

Analyst Rating
0.00 Rating Score
Upside/​Downside
539.0% Upside
$40.00 Price Target
Short Interest
Healthy
0.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of Precipio in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.43 out of 5 stars

PRPO stock logo

About Precipio Stock (NASDAQ:PRPO)

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; and COVID-19 antibody tests. It sells ICE- technology kits to bio-pharma customers. The company is based in New Haven, Connecticut.

PRPO Stock Price History

PRPO Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Precipio, Inc. (PRPO)
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Precipio Continues to Sign New HemeScreen™ Customers
Precipio's Earnings: A Preview
See More Headlines
Receive PRPO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precipio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/23/2018
Today
3/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:PRPO
Employees
53
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$40.00
High Stock Price Target
$40.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+544.8%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-12,200,000.00
Pretax Margin
-68.34%

Debt

Sales & Book Value

Annual Sales
$9.41 million
Book Value
$14.34 per share

Miscellaneous

Free Float
1,269,000
Market Cap
$8.81 million
Optionable
Optionable
Beta
1.61
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

PRPO Stock Analysis - Frequently Asked Questions

What is Precipio's stock price target for 2024?

0 brokerages have issued 12 month target prices for Precipio's stock. Their PRPO share price targets range from $40.00 to $40.00. On average, they expect the company's share price to reach $40.00 in the next year. This suggests a possible upside of 539.0% from the stock's current price.
View analysts price targets for PRPO
or view top-rated stocks among Wall Street analysts.

How have PRPO shares performed in 2024?

Precipio's stock was trading at $6.50 at the beginning of the year. Since then, PRPO stock has decreased by 3.7% and is now trading at $6.26.
View the best growth stocks for 2024 here
.

Are investors shorting Precipio?

Precipio saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 5,000 shares, a decrease of 50.0% from the February 29th total of 10,000 shares. Based on an average trading volume of 6,100 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.4% of the shares of the company are sold short.
View Precipio's Short Interest
.

When is Precipio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our PRPO earnings forecast
.

How were Precipio's earnings last quarter?

Precipio, Inc. (NASDAQ:PRPO) announced its quarterly earnings results on Thursday, August, 23rd. The biotechnology company reported ($3.00) earnings per share (EPS) for the quarter, missing the consensus estimate of $38.60 by $41.60. The biotechnology company earned $0.82 million during the quarter. Precipio had a negative trailing twelve-month return on equity of 62.88% and a negative net margin of 68.39%.

When did Precipio's stock split?

Precipio's stock reverse split on the morning of Friday, September 22nd 2023. The 1-20 reverse split was announced on Friday, September 22nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Precipio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precipio investors own include Biocept (BIOC), Heat Biologics (HTBX), Portola Pharmaceuticals (PTLA), iBio (IBIO), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), VBI Vaccines (VBIV), Co-Diagnostics (CODX), Jaguar Health (JAGX).

Who are Precipio's major shareholders?

Precipio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.71%), Vanguard Group Inc. (2.71%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ahmed Zaki Sabet, David Seth Cohen, Ilan Danieli and Richard A Sandberg.
View institutional ownership trends
.

How do I buy shares of Precipio?

Shares of PRPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRPO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners